Polyclonal Antibody to Killer Cell Lectin Like Receptor Subfamily B, Member 1 (KLRB1)
| Code | Size | Price |
|---|
| PAA986Hu01-20ul | 20ul | £81.00 |
Quantity:
| PAA986Hu01-100ul | 100ul | £148.00 |
Quantity:
| PAA986Hu01-200ul | 200ul | £199.00 |
Quantity:
| PAA986Hu01-1ml | 1ml | £451.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
KLRB1; KLR-B1; CLEC5B; NKR; NKR-P1; NKR-P1A; NKRP1A; HNKR-P1A; Killer Cell Lectin Like Receptor Subfamily B, Member 1; C-type lectin domain family 5 member B; Natural killer cell surface protein P1A
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Cluster Of Differentiation 161
Reactivity:
Ra;Po;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunocytochemistry: 5-20ug/mL;<br/>Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Killer Cell Lectin Like Receptor Subfamily B, Member 1 (KLRB1) | RPA986Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||